Skip to main content Skip to navigation

Euroelso Associates

The objects of the charity are to advance and promote the relief of sickness across Europe through the development and evaluation of novel therapies for support of failing organ systems; maintaining a registry of such novel therapies; supporting clinical research and providing educational programs for medical professionals and lay communities including organising a scientific symposium each year.

Email Charity

Activities & Mission

The objects of the charity are to advance and promote the relief of sickness across Europe through the development and evaluation of novel therapies for support of failing organ systems; maintaining a registry of such novel therapies; supporting clinical research and providing educational programs for medical professionals and lay communities including organising a scientific symposium each year.

Areas of Operation

Where this charity is registered to operate, as self-declared to the Charity Commission. These are regulatory classifications, not a list of active programmes, and don't necessarily indicate fundraising activity in each location.

Show all 27 areas of operation

Financial Information

Latest Income
£139,226
Latest Expenditure
£76,603

Financial Efficiency

Overall Efficiency 55.0%
% of expenditure going to programs (vs overhead)
Expenditure Ratio 55.0%
Expenditure as % of income

Financial Trend

Annual Returns

As filed with the Charity Commission for England and Wales. Most recent filing covers the financial year ending 2024.

One or more years show a significant change in income (over ±100%) compared with the prior year. This usually reflects a merger, transfer of activities, restated accounts, or a one-off legacy — not necessarily a real change in operating scale. See the methodology for context.

Financial YearIncomeExpenditureCharitable SpendingNet AssetsReservesStaff
2024
£139,226
£76,6030 / 0
2023
£42,258
£116,1820 / 0
2022
£57,395
£130,1860 / 0
2021
£21,700
£62,7060 / 0
2020
£170,609
£50,9680 / 0

Staff column shows: Employees / Volunteers

Frequently asked questions about Euroelso Associates

What does Euroelso Associates do?

The objects of the charity are to advance and promote the relief of sickness across Europe through the development and evaluation of novel therapies for support of failing organ systems; maintaining a registry of such novel therapies; supporting clinical research and providing educational programs for medical professionals and lay communities including organising a scientific symposium each year.

How much income did Euroelso Associates report in 2024?

Euroelso Associates reported total income of £139k and reported expenditure of £77k for the financial year ending 2024, based on the most recent annual return filed with the Charity Commission.

When was Euroelso Associates registered as a charity?

Euroelso Associates was registered with the Charity Commission for England and Wales on 12 September 2013 as charity number 1153778. It has been registered for 13 years.

Who runs Euroelso Associates?

Euroelso Associates is governed by a board of 4 trustees. Trustees are legally responsible for the charity's governance and are listed in full on its profile.

Where does Euroelso Associates operate?

Euroelso Associates operates across 27 areas, including Austria, Belgium, Bulgaria and 24 others. The full list is shown on its profile.

Is Euroelso Associates a registered charity?

Yes — Euroelso Associates is a registered charity in England and Wales, charity number 1153778.

Details

Address
c/o Armstrong Watson
First Floor
1 Strawberry Lane
NEWCASTLE UPON TYNE
Registration Date
12 September 2013
Status
Registered

Registry Information

Organisation Number
5036996
Charity Number
1153778

Is this your charity?

Add your logo, photos and tell the story behind the numbers in your own words. Free for our first 50 launch partners.

Claim this listing Learn more about premium profiles

Trustees

Alain Combes
JON SMITH
Simon Finney
Thomas Muller

Sectors & Classifications

Data & trust

Register data refreshed
14 May 2026
Report a data issue